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Results of the Eastern Co-operative Oncology Group (ECOG)
1684 trial of high-dose interferon (HDI) versus observation in
resected stage IIB or III melanoma (primary tumour >4 mm in
depth and/or lymph node involvement) were published in 1996
(Kirkwood et al, 1996). The study was the first to show a statisti-
cally significant improvement in relapse-free and overall survival
in these patients with a high risk of relapse. This was hailed as a
breakthrough in the USA: here at last, after many negative studies,
was an effective treatment. In Europe the response was more
muted, with many oncologists unwilling to submit patients to such
an arduous regimen without further supportive evidence. The
results of the Intergroup E1690 study were therefore disap-
pointing: although the improvement in relapse-free survival with
high-dose treatment seen in the ECOG 1684 trial was confirmed
there was no improvement in overall survival (Kirkwood et al,
2000a). 
The difference in these results is due to an improvement in the
outcome of patients kept under observation in the later trial, there
being an increase in median survival after relapse from 1.8 years in
ECOG 1684 to 4.3 years in E1690. The reasons for this remain
unclear: salvage therapy with interferon at relapse accounts for
some of the increase and there were differences between the two
study populations. Whatever the explanation, these conflicting
reports on the efficacy of HDI have led to only limited uptake of
the regimen in the UK to date. 
A number of studies of low-dose interferon (LDI) in this indica-
tion have also been undertaken. The first major study, conducted
under the auspices of the World Health Organization, showed no
improvement in relapse-free or overall survival for patients with
stage III disease at long-term follow-up (Cascinelli, 1999), a
finding in common with the LDI arm of E1690. Two large trials
have examined LDI treatment in patients with resected stage II
disease, i.e. tumours >1.5 mm in depth without nodal metastases.
An Austrian study of over 300 patients demonstrated increased
disease-free survival for a year of LDI, compared with observa-
tion, but as yet no effect on overall survival (Pehamberger et al,
1998). The larger French study compared 18 months LDI with
observation in 489 patients. Again, there was a clear advantage
for LDI in terms of disease-free survival, and a trend towards
improved overall survival (Grob et al, 1998). Similar results with
only 6 months treatment are published in this issue by the Scottish
Melanoma Group, although the relatively small numbers recruited
to their study preclude meaningful statistical analysis (Cameron
et al, 2001). The UKCCCR AIMHIGH study, which has recently
closed to recruitment, will provide more evidence on the effects of
LDI in the stage IIB and III population. 
Results from the latest Intergroup trial, E1694, are now avail-
able. This study randomized patients between HDI (according to
the regimen in the earlier ECOG studies) and a GM2 ganglioside
vaccine. The study was designed before the results of E1690 were
known, to assess whether the putative benefits of HDI could be
equalled or exceeded by the less toxic vaccine regimen. The trial
was closed by the National Cancer Institute’s Drug Data Safety
Monitoring Committee due to evidence for the clear superiority of
HDI over GM2 vaccination. E1694 recruited 880 patients with
resected stage IIB and III melanoma, stratified for the number of
nodes involved. The planned interim analysis that resulted in study
closure examined the outcome in 774 eligible patients. HDI-
treated patients had improved relapse-free (hazard ratio 1.47;
P = 0.0015) and overall survival (hazard ratio 1.52; P = 0.009)
compared with those vaccinated (Kirkwood et al, 2000b). 
Can HDI now be considered as the treatment of choice for mela-
noma at high risk of recurrence? Unless one postulates a detriment
from GM2 vaccination the results of this latest, and largest,
Intergroup study are compelling. Earlier trials with the vaccine
showed no such detriment (Livingston et al, 1994), there were no
treatment-related deaths in the phase III trial and mounting an anti-
body response to the vaccine did not affect survival. Furthermore,
the survival curve for vaccinated patients in E1694 tracks that of
the observation arm of E1690. 
HDI has a place in the management of melanoma, but questions
remain as to the duration and dose required and the population
who should receive treatment. The lack of understanding of the
basis for interferon’s activity has hampered the search for answers
to these questions. Nevertheless valuable insights can be gained
from the results of clinical trials published to date. Separation of
the survival curves was seen very early in the course of E1684, and
the differences noted in E1694 are apparent after less than 18
months’ follow up. The early, intravenous, component of the HDI
regimen appears important for its effect on melanoma, and it is
unclear what role subsequent intermediate-dose interferon admin-
istration plays. The E1697 trial of the intravenous month of HDI
versus observation in resected T3N0 melanoma may help to
clarify the issue. The imminent results from the EORTC 18952
study will elucidate the role for intermediate doses of interferon as
adjuvant therapy for melanoma. Given the costs and toxicities of
HDI narrower identification of patients who stand to gain from
treatment would be advantageous. The role of established and
novel staging investigations in selecting patients needs to be
defined, and surrogate markers for response identified. However,
none of the studies above was powered to address which sub-
populations most benefit from treatment. It should be noted that
the benefits of HDI identified in the Intergroup studies were
broadly similar in all of the sub-groups making up the high-risk
melanoma population. 
The results of E1694 establish HDI as the benchmark adjuvant
therapy for resected stage IIB and III melanoma. However, ques-
tions remain as to whether the full ECOG regimen is needed and
more precise identification of the population that should be treated
is required in order to offset the acknowledged toxicity of HDI.
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ment shown to improve overall survival although ample evidence
exists for a prolongation of relapse-free survival with LDI. 
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